Trial · NCT07904234
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Neutrophil Engraftment | Up to Day 30 post-transplant | Time from transplant infusion to the first day of absolute neutrophil count (ANC) ≥ 0.5 × 10⁹/L maintained for 3 consecutive days in recipients receiving PBSC products collected using a closed apheresis procedure without gas-phase air exposure. |
| Secondary | pO₂ of PBSC Collection Product | Immediately after PBSC collection | pO₂ level in PBSC collection products collected using a closed apheresis procedure without gas-phase air exposure. |
| Secondary | ROS Levels in CD34⁺ Cells | Day 0 (at collection) | ROS levels in CD34⁺ hematopoietic stem and progenitor cells (HSPCs) collected using a closed apheresis procedure without gas-phase air exposure. |
| Secondary | CD34⁺ HSPC Viability | Day 0 (at collection) | Percentage of viable CD34⁺ hematopoietic stem and progenitor cells (HSPCs) in PBSC products collected using a closed apheresis procedure without gas-phase air exposure. |
| Secondary | CFU Formation Capacity of CD34⁺ HSPCs | Day 0 (at collection) | Colony-forming unit (CFU) formation capacity of CD34⁺ hematopoietic stem and progenitor cells (HSPCs) in PBSC products collected using a closed apheresis procedure without gas-phase air exposure. |
| Secondary | Correlation Between Collection Product pO₂ and Time to ANC Engraftment | Up to Day 100 post-transplant | Correlation coefficient between pO₂ level in PBSC collection products and time to absolute neutrophil count (ANC) engraftment in recipients after transplant. |
| Secondary | Correlation Between Collection Product pO₂ and Time to PLT Engraftment | Up to Day 100 post-transplant | Correlation coefficient between pO₂ level in PBSC collection products and time to platelet (PLT) engraftment in recipients after transplant. |
| Secondary | Time to Platelet Engraftment | Up to Day 100 post-transplant | Time from transplant infusion to the first day of platelet count ≥ 20 × 10⁹/L maintained for 7 consecutive days without platelet transfusion in recipients receiving PBSC products collected by low-oxygen closed apheresis compared with standard apheresis. |
| Secondary | Incidence of Poor Engraftment | Up to Day 100 post-transplant | Proportion of recipients with poor graft function (PGF), defined as cytopenia in at least two cell lineages persisting beyond Day 28 post-transplant with full donor chimerism and absence of relapse or severe GVHD, in recipients receiving PBSC products collected by low-oxygen closed apheresis compared with standard apheresis. |
| Secondary | Early Donor Chimerism | Up to Day 100 post-transplant | Percentage of donor-derived cells (donor chimerism) in recipients after transplant, assessed by flow cytometry. |
| Secondary | Incidence of Donor Adverse Events During and After PBSC Collection | From enrollment to Day 30 post-transplant | Incidence and severity of adverse events in donors during and after PBSC collection using a closed apheresis procedure without gas-phase air exposure, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
| Secondary | Incidence of Recipient Adverse Events After Transplant | From transplant to Day 30 post-transplant | Incidence and severity of adverse events in recipients from transplant to Day 30 post-transplant after receiving PBSC products collected using a closed apheresis procedure without gas-phase air exposure, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07904234/registered